Discover
NCEL
NewcelX Ltd.
3.85
1 x 3.13
2 x 4.13
bid
ask
+
0.18
4.90%
2 @ 04:00 PM
3.73 -0.12 (3.12%)
| Ytd | 102.63% | |
| 1y | -85.02% |
3.40
day range
4.05
1.83
52 week range
28.03
| Open | 3.95 | Prev Close | 3.67 | Low | 3.40 | High | 4.05 | Mkt Cap | 20.73M |
| Vol | 181.53K | Avg Vol | 54.58K | EPS | -2.16 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 3.46 | 200-d Avg | 5.58 | 1yr Est | 0.00 |
NCEL News
benzinga.com
NewcelX Completes Type B Pre-IND Meeting With FDA; Administration Provided Constructive Feedback And
The FDA provided clarity regarding the regulatory pathway toward launching a clinical trial of NCEL-
globenewswire.com
NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Startin
FDA feedback supports NewcelX's planned development strategy for NCEL-101 in combination with Tegopr
benzinga.com
NewcelX Announces Publication Of Peer-Reviewed Study On The Potential Of AstroRx, A Human Embryonic
The publication further validates NewcelX's ability to develop novel cell therapies through its